Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line encorafenib + cetuximab with or without chemotherapy vs standard of care in BRAF V600E metastatic colorectal cancer
2020-001288-99Phase 3Active
- Sponsor
- Pfizer
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of encorafenib in colorectal cancer (CRC) (4 arms), sponsored by Pfizer. Primary endpoint: Safety during safety lead-in. Started Sep 2020; status: active.
02
Drugs
encorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2020-001288-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001288-99.